| EQUITY [Text Block] |
| |
a. |
Composition of share capital:
|
| |
|
June 30,
2022
|
|
|
December 31,
2021
|
|
| |
|
Authorized
|
|
|
Issued and outstanding
|
|
|
Authorized
|
|
|
Issued and outstanding
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares without par value
|
|
Unlimited
|
|
|
|
69,695,325
|
|
|
Unlimited
|
|
|
|
68,217,894
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares confer upon their holders the right to participate in the general meeting where each Common Share has one voting right in all matters, receive dividends if and when declared and to participate in the distribution of surplus assets in case of liquidation of the Company.
| |
b. |
Changes in issued and outstanding share capital:
|
| |
|
Number of
shares
|
|
| |
|
|
|
|
Balance as of January 1, 2022
|
|
|
68,217,894
|
|
| |
|
|
|
|
|
Common Shares issued as a result of options exercised
|
|
|
217,368
|
|
|
Common Shares issued in settlement of purchase consideration of a business combination (1)
|
|
|
1,260,063
|
|
| |
|
|
|
|
|
Balance as of June 30, 2022
|
|
|
69,695,325
|
|
| |
(1) |
Pharm Yarok - 523,700, Vironna - 485,362, Oranim - 251,001
|
The following table lists the movement in the number of share options and the weighted average exercise prices of share options in the 2018 Plan:
| |
|
Six months ended
June 30, 2022
|
|
| |
|
Number of
options
|
|
|
Weighted
average
exercise
price
|
|
| |
|
|
|
|
in CAD
|
|
| |
|
|
|
|
|
|
|
Options outstanding at the beginning of the period
|
|
|
5,443,245
|
|
|
|
3.91
|
|
| |
|
|
|
|
|
|
|
|
|
Options granted during the period
|
|
|
97,500
|
|
|
|
2.13
|
|
|
Options exercised during the period (*)
|
|
|
(227,067
|
)
|
|
|
1.60
|
|
|
Options forfeited during the period
|
|
|
(188,850
|
)
|
|
|
7.63
|
|
| |
|
|
|
|
|
|
|
|
|
Options outstanding at the end of the period
|
|
|
5,124,828
|
|
|
|
3.89
|
|
| |
|
|
|
|
|
|
|
|
|
Options exercisable at the end of the period
|
|
|
2,799,538
|
|
|
|
3.77
|
|
(*) Includes 18,755 Options exercised under cashless mechanism to 9,056 Common Shares.
|